tsh biopharmoration Ltd (8432) - Cash Flow Conversion Efficiency
Based on the latest financial reports, tsh biopharmoration Ltd (8432) has a cash flow conversion efficiency ratio of 0.027x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$42.55 Million ≈ $1.34 Million USD) by net assets (NT$1.58 Billion ≈ $49.73 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See tsh biopharmoration Ltd (8432) liquidity interval to measure how many days the company can operate on defensive assets alone.
tsh biopharmoration Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how tsh biopharmoration Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
tsh biopharmoration Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of tsh biopharmoration Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Italian-Thai Development Public Company Limited
BK:ITD
|
0.490x |
|
Westlin Corporation
NASDAQ:WSTN
|
-0.003x |
|
Arn Media Ltd
AU:A1N
|
0.301x |
|
Remed Co.Ltd
KQ:302550
|
0.006x |
|
Newbridge Acquisition Limited Class A Ordinary Share
NASDAQ:NBRG
|
0.115x |
|
Seres Therapeutics Inc
NASDAQ:MCRB
|
-0.617x |
|
Farmsco
KO:036580
|
0.097x |
|
Alliance Witan Ord
LSE:ALW
|
0.007x |
Annual Cash Flow Conversion Efficiency for tsh biopharmoration Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of tsh biopharmoration Ltd from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see tsh biopharmoration Ltd (8432) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.62 Billion ≈ $51.13 Million |
NT$183.77 Million ≈ $5.79 Million |
0.113x | +323.28% |
| 2023-12-31 | NT$1.27 Billion ≈ $39.89 Million |
NT$33.87 Million ≈ $1.07 Million |
0.027x | -5.57% |
| 2022-12-31 | NT$1.21 Billion ≈ $38.21 Million |
NT$34.35 Million ≈ $1.08 Million |
0.028x | -55.32% |
| 2021-12-31 | NT$1.08 Billion ≈ $34.14 Million |
NT$68.71 Million ≈ $2.16 Million |
0.063x | +515.07% |
| 2020-12-31 | NT$1.13 Billion ≈ $35.49 Million |
NT$11.61 Million ≈ $365.81K |
0.010x | -86.92% |
| 2019-12-31 | NT$1.12 Billion ≈ $35.44 Million |
NT$88.65 Million ≈ $2.79 Million |
0.079x | +41.06% |
| 2018-12-31 | NT$1.12 Billion ≈ $35.31 Million |
NT$62.62 Million ≈ $1.97 Million |
0.056x | -21.05% |
| 2017-12-31 | NT$1.15 Billion ≈ $36.12 Million |
NT$81.13 Million ≈ $2.56 Million |
0.071x | -- |
About tsh biopharmoration Ltd
TSH Biopharm Corporation Limited develops and markets pharmaceutical products in Taiwan. The company offers prescription medication for cardiovascular, central nervous, gastrointestinal, and others. It also provides MPap, a methylation-specific qPCR technology to detect the methylation status of CDO1 and BHLHE22 genes using cervical scraping; AlphaLiquid Detect, a hybrid capture NGS-based liquid … Read more